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Abstract 
Acute respiratory distress syndrome (ARDS) is defined by the association of bilateral infiltrates and hypoxaemia fol‑
lowing an initial insult. Although a new definition has been recently proposed (Berlin definition), there are various 
forms of ARDS with potential differences regarding their management (ventilator settings, prone positioning use, 
corticosteroids). ARDS can be caused by various aetiologies, and the adequate treatment of the responsible cause is 
crucial to improve the outcome. It is of paramount importance to characterize the mechanisms causing lung injury 
to optimize both the aetiological treatment and the symptomatic treatment. If there is no obvious cause of ARDS or if 
a direct lung injury is suspected, bronchoalveolar lavage (BAL) should be strongly considered to identify microorgan‑
isms responsible for pneumonia. Blood samples can also help to identify microorganisms and to evaluate biomarkers 
of infection. If there is no infectious cause of ARDS or no other apparent aetiology is found, second‑line examinations 
should include markers of immunologic diseases. In selected cases, open lung biopsy remains useful to identify the 
cause of ARDS when all other examinations remain inconclusive. CT scan is fundamental when there is a suspicion of 
intra‑abdominal sepsis and in some cases of pneumonia. Ultrasonography is important not only in evaluating biven‑
tricular function but also in identifying pleural effusions and pneumothorax. The definition of ARDS remains clinical 
and the main objective of the diagnostic workup should be to be focused on identification of its aetiology, especially 
a treatable infection.
Keywords: ARDS, CT scan, Ultrasonography, BAL, Diffuse alveolar damage, Personalized medicine, Phenotype–
endotype
Introduction
Acute respiratory distress syndrome (ARDS) is defined 
by the association of bilateral infiltrates and hypoxae-
mia following an initial insult. A new definition has been 
recently proposed [1, 2]. However, one can consider that 
this definition lacks specificity. The recent Lungsafe sur-
vey showed that ARDS is frequently underdiagnosed by 
clinicians [3]. As a consequence protective mechanical 
ventilation is not always implemented in patients who 
are not identified as having ARDS. Another key point 
is that there are various forms of ARDS with potential 
differences regarding their management (i.e. positive 
end-expiratory pressure [PEEP] setting, prone position-
ing use, neuromuscular blockade and occasionally cor-
ticosteroids). Furthermore, adequate treatment of the 
responsible cause is a crucial element in ARDS outcome. 
Common risk factors associated with ARDS are the fol-
lowing: pneumonia, non-pulmonary sepsis, aspiration 
of gastric contents, major trauma, pulmonary contusion, 
pancreatitis, inhalational injury, severe burns, non-car-
diogenic shock, drug overdose, multiple transfusions or 
transfusion-associated acute lung injury (TRALI), pul-
monary vasculitis and drowning [1].
Recent improvements in ARDS outcome are mainly 
related to the decrease in iatrogenic events rather than 
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Take-home message: Although a new definition has been recently 
proposed, there are various forms of ARDS with potential differences 
regarding their management. The main objective of the diagnostic 
workup is to focus on the identification of its aetiology.
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specific treatments, including but not limited to a 
decreased incidence of ventilator-induced lung injury, 
reduced use of sedation, reasonable fluid management 
and improved management of infections. It is therefore 
mandated to recognize the insult causing lung injury 
to better adapt both the aetiological treatment and the 
symptomatic treatment (mainly mechanical ventilation). 
In the following sections, we will identify which priori-
ties in diagnostic procedures to do to identify the cause 
of ARDS and to improve the management.
Initial microbiological assessment of ARDS
As pneumonia is the leading cause of ARDS [4], there is 
the need to adequately identify the pathogen(s) responsi-
ble for infection. Bacteria but also viruses, parasites and 
fungi can cause pneumonia and ARDS. It is also impor-
tant to consider the context including local epidemiol-
ogy, travel history of the patient, recent hospitalization, 
exposure history/sick contacts and immunocompetency. 
Thus, the initial diagnostic workup of ARDS should 
include a systematic microbiological assessment that 
screens for all potential pathogens.
Bacteriological cause of pneumonia
Community-acquired bacterial pneumonia is the most 
frequent cause of direct injury leading to ARDS [4]. There 
is no bacterial specificity, and the usual bacterial causes 
of pneumonia may be responsible for ARDS (Table 1). In 
case of ARDS that develops in mechanically ventilated 
patients, nosocomial pneumonia should be considered as 
a potential cause or aggravating factor [5].
Viral aetiologies of pneumonia
Viruses were historically held responsible for 5–10 % of 
community-acquired pneumonia (CAP) cases, influenza 
being the most frequent [6–8]. However, a recent study 
in patients with severe CAP requiring ICU admission 
found, using polymerase chain reaction (PCR), a 36  % 
rate of virus recovery from the respiratory tract, the vast 
majority being respiratory viruses (Table  1) [9]. These 
viruses can cause severe pneumonia and ARDS. They are 
at best diagnosed on RT-PCR on bronchoalveolar lavage 
[10]. Besides the usual respiratory viruses, herpesviruses 
are an increasing recognized cause of ARDS. In 1982, 
Tuxen et  al. showed that 30  % of their 46 patients with 
ARDS had virological and histological evidence of her-
pes simplex virus (HSV) tracheobronchitis, which could 
be a trigger or an aggravating factor for ARDS [11]. More 
recently, HSV bronchopneumonitis was diagnosed in 42 
(21  %) out of 201 non-immunocompromised patients 
on prolonged mechanical ventilation (after a median of 
12 days of mechanical ventilation), some patients having 
developed ARDS [12]. The diagnosis can be made when 
HSV-specific nuclear inclusion is observed in cells 
recovered by bronchoalveolar lavage (BAL) fluid and/
or by assessing viral load on BAL (threshold at 105 cop-
ies/106  cells) [12]. Cytomegalovirus (CMV) is also a 
well-recognized cause of nosocomial pneumonia in 
non-immunocompromised ICU patients and could be 
associated with ARDS [12, 13]. As for HSV, CMV could 
reactivate in ICU patients as a result of sepsis-induced 
immunoparalysis [14]. While the reactivation is asymp-
tomatic in most patients, a true CMV pneumonia can 
occur in some patients [15, 16].
Fungi and parasites aetiologies
Although fungi are not the usual cause of ARDS, some 
pathogens like Pneumocystis jirovecii, Toxoplasma gondii 
or Aspergillus fumigatus may be responsible for ARDS 
in immunosuppressed patients [17]. Recognizing them 
as potential causes of ARDS in this setting is important 
because a specific treatment could change the outcome 
[17].
Table 1 Most common pathogens responsible for  acute 
respiratory distress syndrome that  should be included 
in the diagnostic workup
MV mechanical ventilation, CAP community-acquired pneumonia, ESBL 
extended-spectrum beta-lactamase, RSV respiratory syncytial virus
a Organisms that cause nosocomial pneumonia and could be responsible for 
ARDS in mechanically ventilated patients
b In immunosuppressed patients
Pathogen
Bacteria Streptococcus pneumoniae
Haemophilus influenza
Enterobacteriaceae
Staphylococcus aureus
Legionella pneumophila
Chlamydia pneumoniae
Mycoplasma pneumoniae
Pseudomonas aeruginosaa
Acinetobacter baumanniia
Stenotrophomonas maltophiliaa
Virus Influenza A and B
Rhinovirus
RSV
Parainfluenza
Metapneumovirus
Coronavirus
Enterovirus
Adenovirus
Bocavirus
Polyomavirus
Herpes simplex virusa
Cytomegalovirusa
Fungi Pneumocystis jiroveciib
Aspergillus fumigatusb
Parasites Toxoplasma gondiib
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Initial diagnostic workup in ARDS patients with suspected 
pneumonia
Because of the potential reversibility of infection-induced 
ARDS, physicians need to systematically investigate an 
infectious aetiology. Initial assessment of a patient with 
ARDS should include a microbiological assessment look-
ing for a wide range of pathogens. Blood cultures, urinary 
antigen testing (for Legionella pneumophila), serologic 
tests (for intracellular bacteria, i.e. Mycoplasma pneu-
moniae, Chlamydia pneumoniae and Legionella pneu-
mophila), and microbial sampling of the lung [18]. Fibre 
optic BAL is a preferred tool for ARDS patients because 
it allows one to recover large amounts of intra-alveolar 
material, although mini-bronchoalveolar lavage is accept-
able also. The first step is a direct microscopic examina-
tion of BAL fluid, which allows one to look for bacteria 
using Gram staining, but also to use Giemsa-modified 
staining which offers a number of advantages over Gram 
staining, including better visualization of host cell mor-
phology (including viral cytopathic inclusions [12]), 
improved detection of bacteria, particularly intracellular 
bacteria, and detection of some protozoan and fungal 
pathogens [19]. The second step is to culture for bacteria 
using quantitative culture of BAL fluid to test for respira-
tory viruses (Table 1), Pneumocystis or other fungi such 
as Aspergillus using PCR [20, 21] (see Table  1). Moreo-
ver, specific staining (immunostaining or immunofluo-
rescence) may be used to detect Legionella pneumophila, 
Pneumocystis jirovecii, Toxoplasma gondii and other 
pathogens responsible for pneumonia in immunocompe-
tent or immunosuppressed patients.
Diagnostic evaluation of suspected lung infection 
complicating the course of ARDS
Fever alerts the clinician that an inflammatory process 
of infectious or noninfectious origin is in progress. Fever 
developing during ARDS represents a difficult diagnostic 
challenge, as underscored by the following. First, clini-
cal criteria have limited value in identifying pulmonary 
or extrapulmonary sources of infections developing dur-
ing ARDS and chest X-ray has low accuracy in this set-
ting [22]. Second, development of multiple concurrent 
infectious processes is a frequent occurrence [23]. Third, 
progressive pulmonary fibroproliferation alone may give 
rise to fever and leukocytosis and be clinically indistin-
guishable from nosocomial pneumonia, thereby making 
a clinical distinction from infections challenging. In one 
study that deployed an extensive diagnostic protocol to 
identify the source of fever, histologically proven fibro-
proliferation was the sole cause in 25  % and ventilator-
associated pneumonia (VAP) in 35  % [23]. Finally, viral 
infection may also cause fever [24, 25]. In this setting, 
HSV and CMV reactivations are frequent and may lead 
to lung involvement (i.e. HSV bronchopneumonitis and 
CMV pneumonia), mimicking bacterial disease [12, 13, 
15, 26].
The diagnostic workup of ARDS patients developing 
fever should thus always be the same: firstly, rule out 
VAP (bacterial and viral), secondly rule out an extrapul-
monary infection, and thirdly look for a non-infectious 
process. If no cause is recognized, ARDS itself (fibro-
proliferation) may be incriminated as the cause of fever 
[23]. In this setting, BAL is probably the best tool, allow-
ing one to look for bacteria, viruses but also for cytology 
or histology in difficult cases. In patients with ARDS, a 
decision regarding the site of bronchoscopic sampling 
is made difficult by the presence of diffuse densities on 
chest radiograph. Bilateral sampling can be one strategy. 
In 94 ARDS patients with suspected VAP, the diagnostic 
yield of bronchoscopy was evaluated with bilateral BAL 
[27]. Thirty-three of the 55 (60  %) positive bronchos-
copies had significant growth in only one side (18 right 
BAL, 15 left BAL). However, the impact of this strategy 
regarding the outcome remains to be validated. Micro-
biological screening should also include searches for spe-
cific microorganisms, namely Herpesviridae: HSV and 
CMV reactivation should be systematically assessed, with 
their virus load quantification using PCR, as well as lung 
involvement, using, if possible, cytologic criteria of viral 
infection [12]. However, the impact of an antiviral treat-
ment regarding the outcome of ICU patients is currently 
under investigation.
Infection surveillance during prolonged 
methylprednisolone treatment
Prolonged methylprednisolone treatment used in 
patients with ARDS blunts the febrile response and the 
physical findings associated with inflammation (i.e. 
abdominal tenderness); therefore, infection surveillance 
is essential to promptly identify and treat nosocomial 
infections [28]. Two randomized trials [29, 30] that incor-
porated infection surveillance (including routine BAL 
every 5–7 days while intubated) identified 56 % of noso-
comial infections in the absence of fever. In addition to 
VAP and catheter-related and/or bloodstream infections, 
patients might be at risk of intra-abdominal infections 
or pancreatitis. Since findings may be misleading, in the 
appropriate clinical setting, computed tomography of the 
abdomen should be considered.
What to do in the absence of usual common risk 
factors for ARDS
Some patients met the radiological and clinical criteria 
of the Berlin definition of ARDS while having none of 
these risk factors. In a recent study, it was shown that the 
prevalence of ARDS with no risk factors was 7.5 % [31]. 
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BAL fluid cytology, chest CT scan and specific immuno-
logic examinations should be done when a classical risk 
factor is not found. Drug-induced acute respiratory fail-
ure should also be considered. In some cases, the clinical 
presentation is explained by a malignant aetiology (ade-
nocarcinoma, lymphangitis). If the diagnosis cannot be 
done by BAL cytology, CT scan or specific biomarkers, 
in some instances there is a role for open lung biopsy in 
order to identify a malignant cause of respiratory failure 
(Fig. 1).
ARDS course and its evaluation
Inflammatory response
As extensively demonstrated, ARDS is often a secondary 
disorder that follows—usually within 6–48 h—a primary 
disease associated with severe systemic inflammation. In 
ARDS, systemic inflammation is activated by the nuclear 
factor-κB (NF-κB) signaling system and potentially 
downregulated by the activated glucocorticoid receptor 
alpha (GRα) [32]. Inflammatory mediators released into 
the systemic circulation (systemic inflammation) from 
the primary insult reach the pulmonary microcirculation 
leading to a stereotypical tissue response consisting of 
three simultaneously NF-κB-activated pathways: (1) tis-
sue inflammation, (2) haemostasis (intravascular clotting 
and extravascular fibrin deposition [hyaline membranes]) 
and (3) tissue repair (regenerating native parenchymal 
cells, fibroproliferation and deposition of extracellular 
matrix) [33]. Clinicians can assess the progression of 
ARDS with daily measurements of variables incorporated 
into the lung injury score (LIS) [34]. On simple physi-
ological criteria, the evolution of ARDS can be divided 
into resolving and unresolving on the basis of achiev-
ing a 1-point reduction in LIS or an increase in PaO2/
FiO2 >100 mmHg by day 7 [34]. Patients with unresolv-
ing ARDS, in contrast to those with resolving ARDS, usu-
ally have histological evidence of maladaptive lung repair 
(Fig. 2) and significantly higher morbidity and mortality 
[33]. As shown in eTable  1 (see electronic supplemen-
tary material), measurement of biomarkers in BAL, as 
well as concurrent plasma samples, has demonstrated a 
strong cause and effect relationship between persistence 
vs. reduction in systemic and pulmonary inflammation-
fibroproliferation and progression (unresolving) vs. 
resolution (resolving) of ARDS, respectively [32]. Nonim-
provers have persistent elevation in circulating and BAL 
levels of inflammatory cytokines, chemokines, markers of 
lung vascular and epithelial permeability and fibrogenesis 
compared to improvers [35–38].
Because 50  % of ARDS patients who had an open 
lung biopsy (and in whom corticosteroids were 
potentially indicated) did not exhibit any sign of 
fibroproliferation by histological analysis [13], the use 
of a specific biomarker of pulmonary fibrosis may be 
useful in early identification of a population that could 
benefit from corticosteroids. Serial assessments of the 
N-terminal peptide for type III procollagen (NT-PCP-
III) in BAL and blood samples are well correlated with 
clinical outcomes [35, 39, 40]. A recent study reported 
that alveolar concentrations of the NT-PCP-III in 
non-resolving ARDS patients was well correlated with 
the presence of lung fibrosis assessed by histological 
examination done on lung biopsies [41]. Future stud-
ies are needed to investigate the use of this biomarker 
to guide the corticosteroids treatment in patients with 
ARDS.
IDENTIFICATION OF USUAL PATHOGENS
fiberoptic BAL or blind sampling technique
+ blood samples + urinary antigen testing
IDENTIFICATION OF UNUSUAL PATHOGENS
viruses, fungi, parasites
fiberoptic BAL (+ cytology) + blood samples
CT scan
specific immunologic exams
improvement of respiratory status
YES NO
improvement of respiratory status
YES NO
improvement of respiratory status
YES NO
OLB
Fig. 1 Simplified representation of the diagnostic strategy for 
identifying the aetiology of ARDS due to pulmonary cause in non‑
immunocompromised patients. BAL bronchoalveolar lavage, OLB 
open lung biopsy
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Histological description of ARDS
In their landmark description of patients with acute 
respiratory distress, Ashbaugh et  al. reported various 
pathologic findings including, but not limited to, intra-
alveolar haemorrhage and oedema, alveolar atelectasis, 
macrophages in the alveolar space, and engorged capillar-
ies as autopsy findings [42]. The most consistent finding 
was the presence of hyaline membranes (HM) in ARDS 
patients. A decade later, Katzenstein, Bloor, and Liebow 
defined the term diffuse alveolar damage (DAD) as a 
manifestation of injury to alveolar lining and endothelial 
cells [43]. In addition to HM, early changes included cap-
illary congestion, focal intra-alveolar oedema, atelectasis 
and intra-alveolar haemorrhage (eTable 2). A later phase 
of DAD past 72  h of ventilation was characterized by a 
mononuclear cell infiltrate of the alveolar space, alveo-
lar epithelial cell hyperplasia and significant interstitial 
fibrosis for most cases ventilated for 8 days or more [43, 
44]. The clinical syndrome has therefore been linked to 
pathologic findings of DAD, and HM in particular [42, 
43]. However, there is evidence that histologic features 
of DAD are becoming less prevalent in the modern era. 
An autopsy study revealed that among patients with risk 
factors for ARDS, a smaller proportion met pathologic 
criteria for HM-positive DAD during the time period of 
2001–2010 compared to the period of 1991–2000 (29 vs 
44 %, p < 0.01) [45]. Tidal volume was also lower in the 
more recent decade. Even for patients with severe ARDS 
by the Berlin definition [2], only 58  % demonstrated 
DAD on autopsy [45]. Pneumonia with abundant neu-
trophils was the dominant pathologic finding in many of 
the clinically defined ARDS cases who did not have DAD 
[46]. Figure 3 provides histologic lung examples of ARDS 
patients with and without HM-positive DAD.
Our understanding of DAD as a pathologic hallmark of 
ARDS is skewed because most pathologic descriptions of 
ARDS derive from autopsy findings. We know very little 
about whether pathologic findings of DAD are prominent 
in milder cases of ARDS or in patients who survive the 
syndrome. In a prospective observational study of open 
lung biopsy for patients with nonresolving ARDS without 
clear aetiology persisting more than 7 days, it was shown 
that the majority demonstrated fibrosis, consistent with 
the fibroproliferative stage of ARDS [13]. However, these 
patients proceeded to biopsy precisely because their 
cause for ARDS was not apparent and their ARDS was 
systemic 
manifestations
pulmonary 
manifestations
(maladaptive 
lung repair)
increased 
rate of 
nosocomial
infections
multiple 
organ 
dysfunction 
syndrome
positive 
fluid 
balance
Increased
BAL 
neutrophils 
and albumin
continuous  
ACM injury  
with vascular 
permeability
neurological 
and 
cardiovascular 
morbidity*
increased 
vascular 
permeability
unrestrained 
coagulation and 
fibroproliferation
failure to 
Improve gas 
exchange and 
lung mechanics 
ventilator 
dependency 
protracted and 
exaggerated 
inflammatory
response
SIRS
(fever)*
Fig. 2 Pathophysiological manifestations of dysregulated systemic inflammation in ARDS. Dysregulated systemic inflammation leads to changes at 
the pulmonary and systemic levels. In the lungs, persistent NF‑κB activation with elevation of inflammatory mediators sustains inflammation with 
resulting tissue injury, alveolar‑capillary membrane permeability, intra‑ and extravascular coagulation in previously spared lobules, and prolifera‑
tion of mesenchymal cells with deposition of extracellular matrix in previously affected lobules, resulting in maladaptive lung repair. This manifests 
clinically with failure to improve gas exchange and lung mechanics and persistent BAL neutrophilia. Systemic manifestations include (1) systemic 
inflammatory response syndrome (SIRS) in the absence of infection, (2) progression of multiple organ dysfunction syndrome (MODS), (3) positive 
fluid balance and (4) increased rate of nosocomial infections. Elevated levels of inflammatory cytokines in the lung favour intra‑ and extracellular 
growth of bacterial pathogens and impair opsonization‑dependent phagocytic neutrophil function and intracellular killing. Additional morbidity 
attributed to elevated cytokinemia includes hyperglycaemia, short‑ and long‑term neurological dysfunction (delirium, neuromuscular weakness, 
post‑traumatic stress disorder, and sudden cardiac events in those with underlying atherosclerosis. Reproduced with permission from [32, 77]
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prolonged; thus, they may not reflect the overall popula-
tion with ARDS. Consonant with the European autopsy 
study, biopsy frequently disclosed infection [13, 45]. His-
tologic patterns may also vary depending on the dura-
tion of ARDS, with oedema and congestion becoming 
less prevalent after a few days with the syndrome while 
fibrosis becomes more prevalent [47], though fibrosis is 
relatively rare among autopsy-diagnosed ARDS [48]. In 
conclusion, it seems unreasonable to conclude that path-
ologic evidence of DAD is the gold standard for ARDS 
diagnosis.
Still a place for open lung biopsies in ARDS patients?
There are two different situations in which lung histol-
ogy could be useful: (1) to diagnose early in the course of 
ARDS a curable aetiology when results from less invasive 
examinations such as BAL, blood samples and CT scan 
are inconclusive and/or (2) towards the end of the first 
week of evolution, to identify fibroproliferation in order 
to consider corticosteroids to improve the outcome in the 
absence of concomitant nosocomial infection. In a series 
of 100 surgical lung biopsies for non-resolving ARDS 
with non-contributive BAL, the presence of fibrosis was 
reported in only 53  % of the cases [13]. Additionally, 
more than half of patients with fibrosis had a concomi-
tant infection [13]. However, it is important to note that 
there has been a significant improvement in the micro-
biologic diagnosis of infectious pneumonia using BAL 
and blood samples. Biomarkers of fibroproliferation such 
as NT-PCP-III measured in BAL were also demonstrated 
to be helpful in the clinical decision-making to initiate 
corticosteroids. Therefore, only a few indications remain 
for open lung biopsy for non-resolving ARDS in current 
clinical practice [49].
Lung imaging
As chest X-ray is part of the ARDS definition and detailed 
elsewhere, its accuracy will be excluded from this review.
CT scan
Lung CT scan has been used to understand the patho-
physiology and the interplay with mechanical ventilation. 
CT scan clearly showed that ARDS is a non-homogene-
ous lung disease with the following classically reported 
morphological patterns: consolidated regions (defined 
by a homogenous increase in density without vessels or 
bronchi), ground glass areas (with an increase in density 
with still recognizable vessels) and the normal aerated 
regions [50]. These three morphological features are usu-
ally simultaneously present. Air bronchograms and small 
pleural effusions are also common. The dependent locali-
zation of consolidated areas is related to the increase in 
lung oedema (i.e. increase in lung weight) during the ini-
tial phase of ARDS which raises the hydrostatic pressure 
transmitted throughout the lung, causing a reduction in 
lung gas volume and the development of non-aerated lung 
regions [51]. These poorly or non-aerated lung regions 
are characterized by a higher inflammation than normally 
ventilated lung regions [52]. The presence of non-inflated 
areas causes a major expansion of the neighbouring lung 
regions and generation of higher local pressures which act 
as a “stress raiser” [52]. Higher amounts of inhomogenei-
ties are accompanied by higher stress raisers and severity 
of ARDS and worse outcome. Pulmonary ARDS presents 
Fig. 3 Representative pathology from two patients with ARDS. a From the post‑mortem lung examination of a 25‑year‑old man who died with 
severe H1N1 influenza confirmed by PCR after 9 days of lung‑protective ventilation. Histology demonstrates extensive hyaline membranes (arrows) 
with evidence of diffuse alveolar damage and a mononuclear cell infiltrate, with apparent loss of alveolar epithelial cells. b Representative section 
from a lung biopsy in a 49‑year‑old woman with moderate ARDS for 5 days and an extensive travel history. All cultures and stains were negative, 
and history demonstrates protein‑rich alveolar oedema with haemorrhage and neutrophils and no hyaline membranes
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a similar amount of consolidated and ground glass areas 
while extrapulmonary ARDS has a higher amount of 
ground glass areas [53]. However, trying to diagnose a 
pulmonary or extrapulmonary ARDS only on the basis 
of CT findings is not accurate. According to lung-pro-
tective strategy, higher levels of PEEP may be indicated 
in patients with more severe disease and higher amounts 
of lung oedema and recruitability [1]. Unfortunately the 
application of PEEP may simultaneously induce a fur-
ther inflation and expansion of the well-inflated regions 
and a decrease in the amount of poorly and non-aerated 
regions (lung recruitment) [54]. Thus higher PEEP levels 
were suggested only in patients with higher recruitabil-
ity (Fig.  4a), avoiding unnecessary higher PEEP levels in 
patients with low recruitability (Fig. 4b). In this way CT 
scan can be useful in describing the distribution of lung 
opacities in order to adapt mechanical ventilation set-
tings. In some instances CT scan is also able to identify 
unsuspected pneumothorax or to help the clinician to 
identify the cause of ARDS (typical lung lesions or intra-
abdominal process causing ARDS).
However the use of CT scan requires the transporta-
tion of the patients to the radiological department, the 
use of ionizing radiation and dedicated software with 
Fig. 4 Representative CT scan imaging from two patients with ARDS. a Patient presenting with homogeneous opacities with a high potential for 
recruitment. b Patient presenting with lung inhomogeneity with a low potential for recruitment
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up to 6  h of work for a complete lung CT scan quanti-
tative computation. Possible solutions include the appli-
cation of a low dose CT scan acquisition protocol (able 
to reduce up to 70 % of the effective dose reduction) [55] 
and the use of a visual anatomical analysis which can 
classify, with a sufficient sensitivity and specificity, the 
patients on the basis of lung recruitability [56].
Lung ultrasonography
Recent analyses of ultrasonographic artefacts produced 
by air, chest wall, pleura and parenchyma have high-
lighted ultrasonography as a valuable tool in the diagnosis 
and management of ARDS [57, 58]. eTable 3 summarizes 
examples of normal and abnormal findings seen with tho-
racic ultrasonography. The most important finding in the 
diagnosis of respiratory failure is a B line (Fig. 5), which is 
defined as a discrete laser-like vertical hyperechoic rever-
beration artefact that arises from the pleural line [58]. It 
extends to the bottom of the ultrasound screen without 
fading and moves synchronously with lung sliding. The 
presence of three or more B lines in one intercostal space 
is considered abnormal and referred to as B pattern [58]. 
It has been shown that B  lines correlate with interstitial 
involvement of the lungs, and B-pattern-predominant 
lungs are suggestive of alveolar processes such as ARDS, 
cardiogenic pulmonary oedema, and unilateral pneu-
monia, rather than nonalveolar causes, such as airway 
obstructive disease and vascular disorders [59]. How-
ever, the presence of bilateral B pattern per se does not 
differentiate ARDS from cardiogenic pulmonary oedema 
as an aetiology of the alveolar process [60]. Ultrasono-
graphic characteristics such as nonhomogeneous distri-
bution of B pattern, pleural line abnormalities (absent or 
reduced lung sliding, thickening or irregularity) and C 
(consolidative) pattern were observed more commonly in 
ARDS compared to cardiogenic pulmonary oedema [61]. 
Combined cardiac and thoracic ultrasonography is able 
to help in differentiation of ARDS from other aetiolo-
gies of acute respiratory failure. While both ARDS and 
cardiogenic pulmonary oedema present with B-pattern-
predominant lungs, it was shown that left pleural effu-
sion, moderately or severely decreased left ventricular 
function, and a large inferior vena cava minimal diameter 
can help in identifying cardiogenic pulmonary oedema 
compared to ARDS in acutely hypoxaemic patients [62]. 
Table  2 summarizes common ultrasonographic findings 
in ARDS and cardiogenic pulmonary oedema. Sequen-
tial thoracic ultrasonography can be used in monitoring 
lung parenchymal changes after the diagnosis of ARDS or 
when there is a sudden severe haemodynamic and/or res-
piratory change suggesting the presence of a pneumotho-
rax. A few studies suggested that the evolution of ARDS 
and VAP could also be successfully followed over time 
with thoracic ultrasonography [63, 64]. Measurement of 
the ultrasound lung reaeration score based on the ultra-
sonographic findings before and after the application of 
PEEP could be as reliable as the pressure–volume curve 
method for assessing lung recruitment [65]. In summary, 
ultrasonography has a role in both the diagnosis and 
management of ARDS. Its portability, non-invasiveness 
and lack of radiation make bedside ultrasonography an 
attractive adjunctive tool to physical examination, labora-
tory data and other imaging studies.
Importantly, new non-invasive promising techniques 
such as electrical impedance tomography may be con-
tributive for diagnosing regional inhomogeneity and lung 
recruitability [66]. Technological improvements would 
contribute to increase its accuracy.
Phenotype identification: personalized medicine 
for ARDS patients?
In asthma, as in many types of cancer, the identification 
of subphenotypes of disease with distinct clinical and 
biological features, different natural histories and differ-
ential response to therapy—also known as “endotypes”—
has dramatically advanced both research and clinical 
care. Over the past several years, there has been increas-
ing evidence for distinct subphenotypes of ARDS, classi-
fied by severity, biology, aetiology, timing, radiographic 
appearance or combinations thereof. How should clini-
cians attempt to incorporate phenotype identification at 
the bedside, now and in future years?
Perhaps the best-accepted and longest-standing 
approach to subphenotyping patients with ARDS is by 
severity of oxygenation impairment i.e. by the PaO2/
FiO2 ratio. This simple and practical approach has 
been incorporated into both the original and newer Fig. 5 Thoracic ultrasonography showing multiple B lines
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Berlin definitions of ARDS [2, 67]. Focusing on moder-
ate–severe ARDS in clinical trials has led to some notable 
successes, including the recent positive trials of neuro-
muscular blockade and prone positioning, with a signifi-
cant impact on clinical practice [68, 69].
Another approach to the identification of distinct 
ARDS subtypes has been to begin with clinically evi-
dent subgroups—e.g. trauma-related ARDS vs. sepsis-
related ARDS, or direct vs. indirect lung injury—and to 
ask whether these subgroups have different biomarkers 
of disease, different histopathology or different clinical 
outcomes [46, 70]. This approach has yielded important 
insights that highlight both the clinical and biological 
heterogeneity within ARDS. For example, patients with 
ARDS from direct pulmonary causes (e.g. pneumonia, 
aspiration) have a biomarker profile that reflects more 
severe lung epithelial injury, while patients with indi-
rect ARDS (e.g. non-pulmonary sepsis) have biomarker 
evidence of more severe endothelial injury and inflam-
mation [71, 72]. Likewise, in a series of elegant studies, 
patients with diffuse ARDS by chest computed tomogra-
phy have lower lung compliance, better response to PEEP, 
and higher levels of the receptor for advanced glycation 
endproducts (RAGE), a marker of lung epithelial injury 
and inflammation, compared to patients with focal ARDS 
[73, 74].
Yet another promising approach has been to adapt well-
established statistical methods to identify meaningful 
subgroups within ARDS, free from presupposition about 
what those subgroups might be. By applying latent class 
models in two large randomized controlled trial samples 
of ARDS patients, investigators found strong evidence 
in both cohorts for two distinct endotypes of ARDS, a 
hyper-inflammatory endotype and a hypo-inflamma-
tory endotype [75]. These two endotypes had different 
clinical and biological features, widely divergent clinical 
outcomes and, perhaps most importantly, differential 
response to randomly assigned treatment with higher vs. 
lower PEEP. Another group of investigators used simi-
lar approaches to analyse data on the timing of ARDS 
in patients with severe trauma; they found evidence for 
early and late ARDS subtypes, as well as some evidence 
of biological differences between the two groups [76].
At the moment, the clinical impact of ARDS pheno-
type identification hinges on whether the division of 
ARDS into specific subphenotypes will improve clini-
cal outcomes. Assessment of severity of ARDS using the 
PaO2/FiO2 ratio already has important implications for 
clinical practice and should be carefully considered in all 
patients. For most of the other proposed subphenotypes 
of ARDS, the question of clinical impact remains open. 
Studies are ongoing to determine if patients with diffuse 
versus focal ARDS respond differently in a randomized 
controlled trial of mechanical ventilation practices 
(NCT02149589), and if the hyper- and hypo-inflamma-
tory subtypes respond differently to randomly assigned 
therapies other than PEEP.
Conclusions
If there is no obvious cause of ARDS or if a direct lung 
injury is suspected, bronchoscopic BAL (or mini-BAL) is 
the pivotal examination in order to identify microorgan-
isms responsible for pneumonia (routine cultures, PCR, 
cytology, direct examination). Blood samples are also help-
ful to identify a microorganism and evaluate biomarkers 
of infection. If there is no infectious cause of ARDS and 
no other apparent aetiology, second-line examinations 
should include common markers of immunologic diseases. 
In selected instances, open lung biopsy remains useful to 
identify the cause of ARDS when all the previous exami-
nations remain inconclusive. CT scan is a fundamental 
examination when there is a suspicion of intra-abdominal 
sepsis and when some agents of pneumonia such as Asper-
gillosis are suspected. Although there is a role of CT scan 
Table 2 Common point-of-care ultrasonography findings in ARDS and cardiogenic pulmonary oedema (CPO)
ARDS CPO
Thoracic ultrasonography
 Bilateral B pattern Bilateral B pattern
  Non‑homogenous distribution   Homogenous distribution
 Pleural line abnormalities Pleural effusion ≥20 mm
  Thickening or irregularity   Left‑sided predominance
  Absent or reduced lung sliding
 C pattern
Cardiac ultrasonography
 Preserved or unchanged left ventricular function from the previous examination New or moderate to severe left ventricular dysfunction
 Normal or small inferior vena cava minimal diameter ≤23 mm Large inferior vena cava minimal diameter >23 mm
 E/e’ ≤8 E/e’ ≥14
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in adjusting ventilator settings, its routine use only for this 
objective is not recommended. Ultrasonography is impor-
tant to evaluate left (and right) ventricular function, and 
also helps in identifying pleural effusions and the presence 
of a pneumothorax. In the presence of non-resolving ARDS 
or when there is a secondary deterioration of the respira-
tory status, BAL (and blood samples) should be used to 
identify the microorganisms that may be responsible for 
VAP. It may also be useful in evaluating biomarkers indicat-
ing fibroproliferation. In this context, open lung biopsy is 
indicated only if there is reasonable suspicion of an undiag-
nosed infection or another process that is masquerading as 
ARDS such as malignancy or immunologic disorders. The 
ARDS phenotype identification sorting ARDS into specific 
subphenotypes could improve clinical outcomes. Ongoing 
and future studies will attempt to assess this latter topic.
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